Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2006

01-04-2006 | Review Article

Glaucoma Medications

Use and Safety in the Elderly Population

Authors: Elliott Kanner, Dr James C. Tsai

Published in: Drugs & Aging | Issue 4/2006

Login to get access

Abstract

As with many diseases, glaucoma increases in frequency in older populations, and is very often encountered in patients taking multiple medications. While the exact mechanism of glaucomatous optic neuropathy (GON) is not known, intraocular pressure (IOP) is thought to be central to the process, and reducing IOP is the only known effective treatment. The newer definition of glaucoma is an IOP-sensitive optic neuropathy. While large, controlled studies have indicated that reducing IOP will slow the progression of disease, the contributions of other conditions and medications have not been adequately studied. As the adverse effect profiles of medical therapies for glaucoma have improved, use of these agents has increased greatly. This has resulted in a large number of older patients taking glaucoma medications. Since topical medications can easily be overlooked in a medical history, and are for the most part well tolerated, systemic complications from these agents can be missed. In addition to being a common disease requiring treatment, glaucoma is also a model system for other degenerative diseases, and many of the concepts originally developed in relation to neurodegenerative diseases such as Alzheimer’s disease are under investigation for glaucoma. These include approaches targeted towards neuroprotection and excitotoxicity.
Literature
1.
Glaucoma. American Academy of Ophthalmology: basic and clinical science course (section 10). San Francisco (CA): American Academy of Ophthalmology, 2003: 3–4
2.
Von Graefe A. Uber die Wirking der Iridetomie bei Glaucom. Arch Ophthalmol 1856; 3: 456–555
3.
Tsai JC, Forbes M. Medical management of glaucoma. 2nd ed. West Islip (NY): Professional Communications, 2004
4.
5.
Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore Eye Survey. Arch Ophthalmol 1991; 109: 1090–5PubMedCrossRef
6.
Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol 2001; 119: 89–95PubMed
7.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–13PubMedCrossRef
8.
Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714–20PubMedCrossRef
9.
Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology 1992; 99: 1499–504PubMed
10.
Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands: the Rotterdam Study. Ophthalmology 1994; 101: 1851–5PubMed
11.
CNTGSG. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma: Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998; 126: 498–505CrossRef
12.
Hayreh SS. Factors influencing blood flow in the optic nerve head. J Glaucoma 1997; 6: 412–25PubMed
13.
Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134–42PubMedCrossRef
14.
Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology 1999; 106: 997–1004PubMedCrossRef
15.
Zeimer RC, Wilensky JT, Gieser DK, et al. Association between intraocular pressure peaks and progression of visual field loss. Ophthalmology 1991; 98: 64–9PubMed
16.
Tsai JC. Intraocular pressure. In: Hitchings RA, editor. Fundamentals of clinical ophthalmology: glaucoma. London: BMJ Books, 2000: 55–61
17.
Chandra V, Bharucha NE, Schoenberg BS. Conditions associated with Alzheimer’s disease at death: case-control study. Neurology 1986; 36: 209–11PubMedCrossRef
18.
Bayer AU, Keller ON, Ferrari F, et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol 2002; 133: 135–7PubMedCrossRef
19.
Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol 2002; 47: 165–8PubMedCrossRef
20.
Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease. Semin Ophthalmol 2003; 18: 50–7PubMed
21.
Wostyn P. Can chronic increased intracranial pressure or exposure to repetitive intermittent intracranial pressure elevations raise your risk for Alzheimer’s disease? Med Hypotheses 2004; 62: 925–30PubMedCrossRef
22.
Wostyn P. Intracranial pressure and Alzheimer’s disease: a hypothesis. Med Hypotheses 1994; 43: 219–22PubMedCrossRef
23.
Silverberg GD, Mayo M, Saul T, et al. Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2003; 2: 506–11PubMedCrossRef
24.
25.
Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol 2003; 48Suppl. 1: S38–46PubMedCrossRef
26.
Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis 2004; 6: S61–74PubMed
27.
Hare W, WoldeMussie E, Lai R, et al. Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol 2001; 45Suppl. 3: S284–9PubMedCrossRef
28.
Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey: II. Structural measures. Invest Ophthalmol Vis Sci 2004; 45: 2640–51PubMedCrossRef
29.
Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey: I. Functional measures. Invest Ophthalmol Vis Sci 2004; 45: 2625–39PubMedCrossRef
30.
Jocson VL, Sears ML. Experimental aqueous perfusion in enucleated human eyes: results after obstruction of Schlemm’s canal. Arch Ophthalmol 1971; 86: 65–71PubMedCrossRef
31.
Toris CB, Yablonski ME, Wang YL, et al. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 1999; 127: 407–12PubMedCrossRef
32.
Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103: 138–47PubMed
33.
DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004; 26: 84–91PubMedCrossRef
34.
Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma 2003; 12: 463–5PubMedCrossRef
35.
Parrish RK, Palmberg P, Sheu WP, et al., for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688–703PubMedCrossRef
36.
Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55–63PubMedCrossRef
37.
Perry CM, McGavin JK, Culy CR, et al. Latanoprost: an update of its use in glaucoma and ocular hypertension. Drugs Aging 2003; 20: 597–630PubMedCrossRef
38.
39.
Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999; 128: 8–14PubMedCrossRef
40.
Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Clin Ther 2000; 22: 103–11PubMedCrossRef
41.
Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000; 22: 167–208PubMedCrossRef
42.
Casson R, James B, Rubinstein A, et al. Clinical comparison of frequency doubling technology perimetry and Humphrey perimetry. Br J Ophthalmol 2001; 85: 360–2PubMedCrossRef
43.
Weintraub M. Intelligent noncompliance with special emphasis on the elderly. Contemp Pharm Pract 1981; 4: 8–11PubMed
44.
Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12: 393–8PubMedCrossRef
45.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310PubMedCrossRef
46.
Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233–6PubMed
47.
Stewart WC, Day DG, Holmes KT, et al. Effect of timolol 0.5% gel and solution on pulmonary function in older glaucoma patients. J Glaucoma 2001; 10: 227–32PubMedCrossRef
48.
Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97: 86–92PubMed
49.
Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000; 84: 710–3PubMedCrossRef
50.
Malnick SD, Gelzer G, Attali M. Fatal respiratory arrest following timolol ophthalmic solution. MedGenMed 2001; 3: 12PubMed
51.
Ostergaard LS, Bjerrum P. Timolol eyedrop-induced severe bronchospasm. Acta Med Scand 1982; 211: 505–6
52.
Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 2002; 134: 749–60PubMedCrossRef
53.
Sharifi M, Koch JM, Steele RJ, et al. Third degree AC block due to ophthalmic timolol solution. Int J Cardiol 2001; 80: 257–9PubMedCrossRef
54.
Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 1999; 128: 301–9PubMedCrossRef
55.
Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma: Night Study Group. Am J Ophthalmol 1997; 123: 465–77PubMed
56.
Hepsen IF, Yildirim Z, Yilmaz H, et al. Preventive effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin Experiment Ophthalmol 2004; 32: 597–602PubMedCrossRef
57.
Fraunfelder FT, Meyer SM. Systemic side effects from ophthalmic timolol and their prevention. J Ocul Pharmacol 1987; 3: 177–84PubMedCrossRef
58.
Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol: Brimonidine Study Groups 1 and 2. Ophthalmology 2000; 107: 1171–7PubMedCrossRef
59.
Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002; 11: 119–26PubMedCrossRef
60.
Physician’s Desk Reference. 59th ed. Montvale (NJ): Thomson, 2005
61.
Schweitzer I, Maguire K, Tuckwell V. Antiglaucoma medication and clinical depression. Aust N Z J Psychiatry 2001; 35: 569–71PubMedCrossRef
62.
Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004; 18: 24–6PubMedCrossRef
63.
Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2%) [in French]. J Fr Ophtalmol 2000; 23: 763–8PubMed
64.
Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995; 113: 77–83PubMedCrossRef
65.
Frishman WH, Kowalski M, Nagnur S, et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. Heart Dis 2001; 3: 386–97PubMedCrossRef
66.
Yoles E, Wheeler L, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40: 65–73PubMed
67.
Gandolfi S, Cimino L, Mora P. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short-term clinical trial. Eur J Ophthalmol 2003; 13: 611–5PubMed
68.
Lippa EA. Carbonic anhydrase inhibitors. In: Ritch R, Shields MB, editors. Glaucomas. St Louis (MO): Mosby-Year Book, 1996
69.
Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001; 108: 1023–31PubMedCrossRef
70.
Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001; 132: 472–84PubMedCrossRef
71.
Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol 2002; 133: 1–10PubMedCrossRef
72.
Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45Suppl. 4: S361–8PubMedCrossRef
73.
Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension: the Latanoprost Study Group. Ophthalmology 1996; 103: 126–37PubMed
74.
Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134–42PubMedCrossRef
75.
Orzalesi N, Rossetti L, Bottoli A, et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453–7PubMedCrossRef
76.
Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003; 12: 466–9PubMedCrossRef
77.
Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999; 127: 602–4PubMedCrossRef
78.
Hedner J, Svedmyr N, Lunde H, et al. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma. Surv Ophthalmol 1997; 41Suppl. 2: S111–5PubMedCrossRef
79.
Hedner J, Everts B, Moller CS. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch Ophthalmol 1999; 117: 1305–9PubMed
80.
Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004; 1: 101–10PubMedCrossRef
81.
Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 1999; 117: 1540–4PubMedCrossRef
82.
Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433: 73–7PubMedCrossRef
83.
Coleman AL, Singh K, Wilson R, et al. Applying an evidence-based approach to the management of patients with ocular hypertension: evaluating and synthesizing published evidence. Am J Ophthalmol 2004; 138: S3–10PubMedCrossRef
84.
Girkin CA, Kannel WB, Friedman DS, et al. Glaucoma risk factor assessment and prevention: lessons from coronary heart disease. Am J Ophthalmol 2004; 138: S11–8PubMedCrossRef
85.
Friedman DS, Wilson MR, Liebmann JM, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004; 138: S19–31PubMedCrossRef
86.
Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943–53PubMedCrossRef
Metadata
Title
Glaucoma Medications
Use and Safety in the Elderly Population
Authors
Elliott Kanner
Dr James C. Tsai
Publication date
01-04-2006
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2006
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200623040-00005

Other articles of this Issue 4/2006

Drugs & Aging 4/2006 Go to the issue

Original Research Article

Medication Nonadherence and Subsequent Risk of Hospitalisation and Mortality among Older Adults

Review Article

Diastolic Heart Failure in the Elderly and the Potential Role of Aldosterone Antagonists

Current Opinion

Use of Sleep-Promoting Medications in Nursing Home Residents

Review Article

A Comparative Review of Apomorphine Formulations for Erectile Dysfunction

Review Article

Long-Term Safety of Bisphosphonate Therapy for Osteoporosis

Original Research Article

Use of Inappropriate Medications and Their Prognostic Significance Among In-Hospital and Nursing Home Patients with and without Dementia in Finland
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits